FRONT-2 enrolled treatment-naïve and recently diagnosed treatment-experienced wet AMD patients, unlike the ...
Diana Canto-Sims, OD, owner of Buena Vista Optical, discusses how Meta's donation of free AI glasses to blind veterans could ...
Memento Medicines, a privately held biotech developing biologic therapies for retinal disease, has launched with a $93 ...
Training a computer vision model on a 50:50 blend of synthetic and real eye images produces more reliable segmentation of the ...
Bayer acquired Perfuse Therapeutics and its experimental endothelin-blocking eye implant PER-001, and partnered with AI firm ...
The US Food and Drug Administration has accepted for review the Biologics License Application (BLA) for ONS-5010 (LYTENAVA) ...
Belite Bio has completed its rolling NDA submission to the FDA for tinlarebant, a potential first approved treatment for ...
The 2-day program at the Gaylord Opryland Resort will bring together established and emerging eye care leaders for sessions ...
NCX 470 glaucoma drop gains China regulatory encouragement, clearing path for near-term filings and expanding commercial ...
Conventional SLT requires gonioscopy-lens visualization; DSLT fires 120 pulses (1.8 mJ, 50 Hz) transsclerally with eye tracking, completing most sessions without contact. At 2 months, mean IOP fell ...
In this podcast, experts Mary Qiu, MD; Paul Singh, MD; and Danica J. Marrelli, OD, FAAO; discuss interventional glaucoma. This more proactive management approach aims to minimize the challenges of ...
Priority review positions satralizumab as a potentially practice-shifting alternative to IV IGF-1R inhibitors, primarily differentiated by subcutaneous self-administration and at-home dosing. Two ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results